Cambrex, a leading global contract development and manufacturing organization, is celebrating the completion of its $38 million capacity expansion at its small molecule active pharmaceutical ingredient manufacturing facility in High Point.
Read More
Cambrex Corp., a contract manufacturer of small-molecule therapeutics with major facilities in High Point and Durham, plans to invest another $30 million and hire 78 more employees to expand the production capabilities of its High Point campus.
Read More
Cambrex Corp., a global provider of small-molecule drug services with growing operations in High Point and Durham, has finished an expansion of its biopharmaceutical analysis capabilities in Durham.
Read More
Two drug manufacturing companies with operations in North Carolina will become one company through a $252 million deal announced Tuesday.
Read More
Life sciences company Cambrex is expanding its High Point operation through a building acquisition as well as a tripling of its workforce at the location.
Read MoreCambrex Corp., a contract manufacturer of small molecules and active pharmaceutical ingredients (APIs) for drug clinical trials, is expanding again in High Point to meet growing business demand for its services.
Read More
